Literature DB >> 76932

Induction of remission in hepatocellular carcinoma with doxorubicin.

P J Johnson, R Williams, H Thomas, S Sherlock, I M Murray-Lyon.   

Abstract

Doxorubicin (60 mg/m2 at 3-weekly intervals to a maximum total of 550 mg/m2) induced clinical remission in 14 (32%) of 44 patients with hepatocellular carcinoma. In 3 of those who responded, hepatic arteriography showed clearing of the previously extensive tumour circulation, and in a 4th there was disappearance of the tumour on serial ultrasound examinations. A fall in serum-alpha-fetoprotein level after the initial injection of doxorubicin predicted a favourable clinical response, whereas the level continued to rise in patients who did not respond.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 76932     DOI： 10.1016/s0140-6736(78)90735-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  26 in total

1.  Myrtenal attenuates diethylnitrosamine-induced hepatocellular carcinoma in rats by stabilizing intrinsic antioxidants and modulating apoptotic and anti-apoptotic cascades.

Authors:  Lingaiah Hari Babu; Srinivasan Perumal; Maruthaiveeran Periyasamy Balasubramanian
Journal:  Cell Oncol (Dordr)       Date:  2012-06-22       Impact factor: 6.730

2.  A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

Authors:  J J Knox; X E Chen; R Feld; M Nematollahi; R Cheiken; G Pond; J A Zwiebel; S Gill; M Moore
Journal:  Invest New Drugs       Date:  2007-12-04       Impact factor: 3.850

Review 3.  Advances in neoplastic disease of the liver and biliary tract.

Authors:  P J Johnson; M L Wilkinson; J Karani
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Spontaneous regression of hepatocellular carcinoma.

Authors:  R C Ayres; D A Robertson; K C Dewbury; G H Millward-Sadler; C L Smith
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

5.  Lung metastases from a primary hepatocellular carcinoma.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1980-04       Impact factor: 9.139

6.  Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma.

Authors: 
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 7.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  In vitro and in vivo cytotoxic activity of native and ricin conjugated monoclonal antibodies to HBs antigen for Alexander primary liver cell carcinoma cells and tumours.

Authors:  J M Oladapo; A H Goodall; R de Koning; J Parmar; D Brown; H C Thomas
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

9.  Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension: a pilot clinico-pharmacological study.

Authors:  T Ichida; M Kato; A Hayakawa; M Watanabe; K Igarashi; K Hata; Y Doya; M Miura; H Sato; H Asakura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.